Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Mirvetuximab soravtansine plus Bevacizumab
DRUG: Bevacizumab

Sponsor

AbbVie

Collaborators

[object Object]